SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist
about
Endothelin-1 and the periaqueductal gray area of the rat: an autoradiographic and functional pharmacological study.Endothelin: what does the radiologist need to know?Coronary vasoconstriction in vitro in the hearts of polyarthritic rats: effectiveness of in vivo treatment with the endothelin receptor antagonist SB 209670Conditions permitting suppression of stretch-induced and vasoconstrictor tone by basal nitric oxide activity in porcine cerebral artery.Cardiovascular effects of endothelin-1 and endothelin antagonists in conscious, hypertensive ((mRen-2)27) ratsEndothelin receptor subtype distribution predisposes coronary arteries to damage.Cardiopulmonary indications for endothelin receptor antagonists: review of recent efficacy trials.Endothelin-1 and the regulation of vascular tone.Endothelin receptor antagonist increases cerebral perfusion and reduces ischaemic damage in feline focal cerebral ischaemia.Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing.Systemic hypertension induced by hepatic overexpression of human preproendothelin-1 in rats.Inhibitors of endothelin.Organocatalytic synthesis of chiral tetrasubstituted allenes from racemic propargylic alcohols.The endothelin system in cardiovascular physiology and pathophysiology.In vivo pharmacological characterization of the non-peptide endothelin receptor antagonist SB 209670.Effects of the endothelin receptor antagonist, SB 209670, on circulatory failure and organ injury in endotoxic shock in the anaesthetized rat.Temporal differences between the involvement of angiotensin II and endothelin in the cardiovascular responses to endotoxaemia in conscious rats.Influence of aminoguanidine and the endothelin antagonist, SB 209670, on the regional haemodynamic effects of endotoxaemia in conscious rats.Effect of selective blockade of endothelin ETB receptors on the liver dysfunction and injury caused by endotoxaemia in the ratPharmacological evidence for the presence of three distinct functional endothelin receptor subtypes in the rabbit lateral saphenous vein.Effects of dexamethasone and SB 209670 on the regional haemodynamic responses to lipopolysaccharide in conscious rats.Comparison of endothelin B (ETB) receptors in rabbit isolated pulmonary artery and bronchusTrigeminal nerve ganglion stimulation-induced neurovascular reflexes in the anaesthetized cat: role of endothelin(B) receptors in carotid vasodilatation.Enhancement of the haemodynamic effects of NG-monomethyl-L-arginine by transforming growth factor-beta 1 in conscious, normal, but not endotoxaemic, ratsEnhancement of the hypotensive and vasodilator effects of endotoxaemia in conscious rats by the endothelin antagonist, SB 209670.Altered mitogen-activated protein kinase activation in vascular smooth muscle cells from spontaneously hypertensive rats.Roles of endothelin receptors in the regional and systemic vascular responses to ET-1 in the anaesthetized ganglion-blocked rat: use of selective antagonists.Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats.Endothelin-mediated vascular tone following focal cerebral ischaemia in the cat.The effect of radiographic contrast media on human vascular smooth muscle cells.Dipeptide sulfonamides as endothelin ETA/ETB receptor antagonists.
P2860
Q30498780-9F40C02B-DBB4-4736-8A9B-D0D7A65EBACDQ34155501-AB618DFE-F215-4A92-A520-90B8B2068029Q34793001-2FAAA157-AF57-4FA5-850D-7ACE54F6160DQ35042307-D10D9AFA-1E08-4019-91AC-FA047AF1E27DQ35043061-1168BF71-38A6-4437-AC45-3B165350CEE2Q35746003-00166CD0-A60D-46A6-9AA5-DFB72CFEBE20Q36179755-E1AEE136-B24D-4ECE-9F5C-7C5F23711B71Q36680915-ACBFE001-D8A5-4082-877C-AFE0FC66FCC5Q36817047-DF0A82A3-8925-48D3-A027-BF7236FA153AQ37359804-203F42E6-CBD6-4558-A5E5-0D9B9E11D751Q37361568-D6876155-C8AC-4521-B675-B3B1DE4A94D8Q41287170-97CB4F26-285B-4D96-AEBA-3D4398AA6082Q41701276-F5238FAC-CC8B-4552-9D9D-60A5C1CDB3A5Q41740408-8AADF69B-F330-4D97-98C6-CE00CFD3CCD8Q41790468-EB171EE3-EA72-4E05-AA73-BF1D0CE82491Q41790851-77BA6005-6756-4378-B722-C5CA2C297E83Q41837857-881E0170-1729-4AB5-BC45-4FC7393954EFQ41840927-4704789E-1828-4AF9-897A-90E19CAA2EB7Q41841070-11554879-EE57-4DBC-A22B-329BCDD9ADD9Q41893093-5994D3AE-3649-436D-B5C8-94108D8445EFQ42040897-4291A997-A38F-4C22-BC12-AAE73D594932Q42089071-55D57EA9-5140-4058-9DBD-44643F61BAFCQ42116885-912B7732-A9EA-4492-9B33-79C0ECE8A4C1Q42143323-1AFB6D86-2B39-446D-9A6C-A0EEE82199B1Q42234187-BA758A0F-A65B-4038-A600-1C5914430E11Q42522237-19C0E3BA-400D-465A-A084-8B1C2BBBEC89Q42707758-92147EA2-1CF4-47DB-9C0C-49F9BBB876D4Q42708365-47829690-4A39-434A-8612-D83D7191F23FQ48968940-8702ED5E-9732-4AE9-AFDD-C03B565E117AQ50523483-A110239E-F3D8-42AF-99CE-E79064CAA98CQ53968500-039A4DE1-B67E-4A33-8FC8-4F4FFF02CB49
P2860
SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist
@ast
SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist
@en
type
label
SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist
@ast
SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist
@en
prefLabel
SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist
@ast
SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist
@en
P2093
P2860
P356
P1476
SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist
@en
P2093
Cousins RD
Douglas SA
Edwards RM
Ohlstein EH
P2860
P304
P356
10.1073/PNAS.91.17.8052
P407
P577
1994-08-01T00:00:00Z